HR Execs on the Move

Path-Tec

www.Path-Tec.com

 
Path-Tec is a leading provider of specimen collection kits and components. Our specialty is detailed specimen management. We understand the importance of specimen integrity so we work with laboratories to design kits that assist with proper specimen co...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.Path-Tec.com
  • 5700, Old Brim Road
    Columbus, GA USA 31820
  • Phone: 706.569.6368

Executives

Name Title Contact Details
Tracey McLaurin
Vice President, Head of Human Resources Profile

Similar Companies

The Center for Health Care Services

MAKE AN APPOINTMENT Adult: 210.261.1250 Children: 210.261.3350   The Center for Health Care Services (CHCS) is proud to present our Annual Report for Fiscal Year 2018. By making Our People, Our Community, Our Priority; CHCS is changing lives, restoring...

Pathalys

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.

GENACTICS

GENACTICS is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

HumanCo

HumanCo is a mission-driven private holding company that invests in and builds brands focused on healthier living and sustainability.

Context Therapeutics

Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.